Cjc-1295 With Dac - 5MG
About Cjc-1295 With Dac - 5MG
CJC-1295 is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH), based on the biologically active GHRH(1-29) fragment. The peptide incorporates four amino-acid substitutions (positions 2, 8, 15 and 27) engineered to increase resistance to enzymatic degradation, most notably cleavage by dipeptidyl peptidase-IV (DPP-IV). This substituted backbone is the same core sequence marketed in research contexts as "Modified GRF (1-29)." In laboratory model systems it is studied as a tool for probing GHRH-receptor signaling and pulsatile growth-hormone release from the anterior pituitary.
Two forms circulate in research use. The "No DAC" form (Mod GRF 1-29) is the unconjugated peptide with a short plasma half-life, used to model discrete, transient GHRH pulses. The "With DAC" form appends a Drug Affinity Complex (DAC) moiety that binds serum albumin, substantially extending circulating half-life and enabling investigation of sustained GHRH-receptor exposure. The identity data listed here correspond to the No DAC (Mod GRF 1-29) backbone; the DAC form carries an additional lysine-linked maleimidopropionic acid conjugate and a correspondingly higher molecular weight. All material is supplied for laboratory research only.
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
Handling and Storage Tips:
Keep peptides cold and away from light once received.
For short-term use (days to weeks), refrigeration at 4°C (39°F) is acceptable.
Lyophilized peptides are typically stable at room temperature for several weeks, making it suitable for moderate-term storage.
For long-term storage (months to years), it’s best to freeze peptides at -80°C (-112°F). Freezing optimally preserves peptide stability for extended periods.
FDA Disclosure & Intended Use:
FDA Disclosure: The statements on this website and the products sold herein have not been evaluated by the U.S. Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. Products sold are for Research Use Only and are not for human or animal use.
Intended Purpose: Products sold on this site are intended solely for basic laboratory research, pharmaceutical research, or the development of new tests. They are not intended for diagnostic, therapeutic, or clinical use.
Specifications
- MaterialCjc-1295 With Dac - 5MG
- Also searched asCJC1295, CJC 1295
- Research AreaGrowth Hormone Research
- Presentation—
- CAS Number863288-34-0
- Molecular FormulaC152H252N44O42
- Molecular Weight3367.9 g/mol
- TypeSynthetic peptide (GHRH analog)
- Receptor / TargetGrowth hormone-releasing hormone receptor (GHRH-R)
- PubChem CID56841945 →
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
- Purity (HPLC)≥99%
- Identity (MS)Confirmed to specification
- TestingAccredited (ISO 17025) third-party laboratory
- DocumentationPer-batch COA →
Published research on the CJC-1295 backbone has focused on the pharmacokinetic consequences of DPP-IV-resistant substitutions and albumin conjugation. Studies of the DAC-conjugated form report markedly prolonged circulating half-life relative to native GHRH, with sustained elevation of GH and IGF-1 in animal and early clinical model systems, whereas the unconjugated Mod GRF (1-29) form is characterized by rapid clearance and short, discrete secretory responses.
Comparative work in the GHRH-analog class has examined how conjugation strategy influences the amplitude and pattern of GH pulses, making CJC-1295 a frequently cited experimental system for distinguishing sustained-exposure from pulsatile GHRH-receptor stimulation.
CJC-1295 was developed in the early 2000s by ConjuChem Biotechnologies as part of a program applying Drug Affinity Complex technology to peptide hormones, extending GHRH(1-29) half-life by covalent conjugation to circulating albumin. The unconjugated substituted backbone (Modified GRF 1-29) subsequently became a widely used short-acting research counterpart, and both forms remain common reference tools in growth-hormone-axis studies.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Jette L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.
- Alba M, et al. Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. This material is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
Are these research materials third-party tested?
Yes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.
What purity are the materials?
Materials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.
Do you provide a Certificate of Analysis (COA)?
Yes. Per-batch COA documentation is provided and is traceable by lot number.
Where do you ship from?
Materials are shipped from the USA in discreet, protective packaging.
Are these products for human use?
No. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.
More Growth Hormone Research materials
✓ ≥99% View COA ›
IGF-1 LR3 1MG Research Vial - Long-Acting IGF-1 Analogue | Third-Party Tested
RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE · 21+
